Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
11 hedge funds and large institutions have $46.7K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
38% more funds holding
Funds holding: 8 → 11 (+3)
30% less capital invested
Capital invested by funds: $66.8K → $46.7K (-$20.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$13.5K |
| 2 |
VF
Virtu Financial
New York
|
+$12.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$6.86K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$8.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.89K |
| 4 |
SRCM
Signature Resources Capital Management
Newport Beach,
California
|
-$35 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $15.5K | +$7.4K | +557 | +50% |
|
|
VF
2
Virtu Financial
New York
| $9K | +$12.6K | +946 | New |
|
|
HF
3
HRT Financial
New York
| $9K | +$13.5K | +1,015 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $4.98K | -$3.89K | -293 | -36% |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $4.77K | +$6.86K | +516 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.95K | +$2.09K | +157 | +103% |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $228 | +$319 | +24 | New |
|
8
Morgan Stanley
New York
| $190 | +$253 | +19 | +1,900% |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $91 | +$133 | +10 | New |
|
|
VWM
10
Vermillion Wealth Management
Rosemount,
Minnesota
| $38 | +$53 | +4 | New |
|
11
Bank of America
Charlotte,
North Carolina
| $25 | +$27 | +2 | +200% |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$21.8K | -1,255 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$8.7K | -501 | Closed |
|
|
SRCM
14
Signature Resources Capital Management
Newport Beach,
California
| – | -$35 | -2 | Closed |
|
VRPX Hedge Fund Activity: Q4 2024 in Review
11 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q4 2024, worth a combined $46.7K — down 30% from $66.8K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VRPX positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $13.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $21.8K sold.
- 11 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q4 2024, up from 8 in Q3 2024.
- Funds reported $46.7K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q4 2024, down 30% quarter-over-quarter.
- 6 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q4 2024 and 3 closed out, a net change of +3 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q4 2024 was HRT Financial, an estimated $13.5K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q4 2024 was Citadel Advisors, an estimated $21.8K sold.
Based on aggregated 13F filings for Q4 2024.